India Pharma Outlook Team | Friday, 23 October 2026
Two-year late-stage clinical trial results suggest that Vor Bio’s kidney drug telitacicept could slow down kidney function decline in patients with immunoglobulin A nephropathy (IgA nephropathy).
The results could boost the drug’s prospects for development, although they raise a bigger question: whether clinical trial data gathered from China can support regulatory approval filings elsewhere.
Developed by China-based RemeGen and licensed to Vor Bio for markets outside Greater China, telitacicept targets two proteins involved in immune-system activity.
The results also highlight a key issue in kidney disease research: whether a treatment can preserve the kidneys’ filtering capacity over time, rather than simply improve an earlier laboratory marker.
The Phase 3 TELIGAN trial evaluated telitacicept in patients with IgA nephropathy, a chronic kidney disease in which deposits of the immunoglobulin A antibody contribute to inflammation and damage in the kidney’s filtering units.
The final analysis followed estimated glomerular filtration rate (eGFR), which indicates how well the kidneys filter waste from the blood, through Week 104. The results showed a smaller decline in kidney function among patients receiving telitacicept than among those receiving placebo.
The results are significant because IgA nephropathy can progressively damage the kidneys, potentially leading to kidney failure.
However, the results do not establish that telitacicept can prevent kidney failure in every patient or demonstrate its superiority over other approved treatments.
Also Read: How Data-Driven Pharma Strategy Can Accelerate Sustainable Growth
Proteinuria, or excess protein in urine, is an important indicator of kidney damage and a commonly used endpoint in IgA nephropathy trials.
However, reductions in proteinuria and preservation of kidney function are different measures of treatment response.
The distinction matters for three reasons:
Although Vor Bio’s kidney drug has generated encouraging late-stage data, international regulatory acceptance remains an important consideration. The TELIGAN study was conducted in China, where RemeGen developed telitacicept.
The company’s ability to translate the findings into broader markets will depend on regulatory review, the total clinical evidence package and any additional studies required by authorities.
The development also reflects a wider pharmaceutical industry trend: companies are increasingly pursuing regional drug-development partnerships to expand the potential reach of clinical-stage therapies.
For telitacicept, the next challenge is to establish whether its efficacy and safety profile can support further development and eventual approval in additional markets.
.jpg)
